

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: ULKCMLP

Page 1 of 1

A BC Cancer "Compassionate Access Program" request form must be completed and approved prior to treatment

DOCTOR'S ORDERS Htcm Wtkg BSA_	m²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form	
DATE: To be given: Cy	/cle #:
 □ Delay treatment week(s) May proceed with doses as written if within 7 days of PONAtinib initiation, then within 10 days of dispensing the next cycle for first 6 months of therapy; thereafter, within 28 days of dispensing the next cycle. • ANC greater than or equal to 1.5 x 10⁹/L, platelets greater than or equal to 75 x 10⁹/L. Dose modification for: □ Hematology □ Cardiac Risk □ Diarrhea □ Other Toxicity 	
TREATMENT:	
PONAtinib ☐ 45 mg (standard dose) or ☐ 30mg or ☐ 15mg (select one) PO once daily	
Mitte: months (1-month supply for first 6 months of therapy; may dispense 3-month supply after 6 months)	
Refill x	
RETURN APPOINTMENT ORDERS	
Return in weeks for Doctor and cycle	
CBC & Diff, serum lipase every 2 weeks for the first 3 months	
Echocardiography at 3 months	
Months 1-3: ALT, total bilirubin monthly or as clinically indicated	
After 3 months:	
CBC & Diff monthly ALT, total bilirubin monthly and as clinically indicated (in patients with transaminase elevations, perform hepatic enzyme tests more frequently) Sodium, potassium, magnesium, calcium, phosphorous, serum lipase every 3 months or as clinically indicated	
Peripheral blood analysis for quantitative RT-PCR (for BCR/ABL transcripts) every 3 months and mutational analysis	
As clinically indicated: Echocardiography ECG HBV viral load Other tests: Consults: See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: